Mucopolysaccharidosis VII Disease Monitoring Program (MPS VII DMP)
Phase of Trial: Phase IV
Latest Information Update: 24 Nov 2018
At a glance
- Drugs Vestronidase alfa (Primary)
- Indications Mucopolysaccharidosis VII
- Focus Adverse reactions; Therapeutic Use
- Acronyms MPS VII DMP
- Sponsors Ultragenyx Pharmaceutical
- 15 Nov 2018 Planned End Date changed from 1 Apr 2032 to 1 May 2033.
- 15 Nov 2018 Planned primary completion date changed from 1 Apr 2032 to 1 May 2033.
- 03 Aug 2018 New trial record